Clinical Trials Logo

Clinical Trial Summary

This is an open-label trial investigating the efficacy of temsirolimus in recurrent or refractory primary CNS lymphoma (PCNSL) after initial chemotherapy with a high-dose methotrexate containing regimen. 37 patients are planned to be treated with weekly infusions of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months. The trial is designed in two stages, if less than one of the first 12 patients responds to treatment, the trial is stopped. In addition to efficacy, safety and penetration of temsirolimus into the cerebrospinal fluid will be investigated.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Lymphoma
  • Recurrent or Refractory Primary CNS Lymphoma

NCT number NCT00942747
Study type Interventional
Source Charite University, Berlin, Germany
Contact Agnieszka Korfel, MD
Phone +49308445
Email agnieszka.korfel@charite.de
Status Recruiting
Phase Phase 2
Start date July 2009
Completion date June 2014